Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
1370449 | Bioorganic & Medicinal Chemistry Letters | 2011 | 5 Pages |
Abstract
It has been demonstrated that once-a-day dosing of systemically-distributed SCD inhibitors leads to adverse events in eye and skin. Herein, we describe our efforts to convert a novel class of systemically-distributed potent triazole-based uHTS hits into liver-targeted SCD inhibitors as a means to circumvent chronic toxicity.
Graphical abstractStudy to convert systemically-distributed SCD uHTS hits into liver-targeting inhibitors is described.Figure optionsDownload full-size imageDownload as PowerPoint slide
Keywords
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
Jean-Philippe Leclerc, Jean-Pierre Falgueyret, Mélina Girardin, Jocelyne Guay, Sébastien Guiral, Zheng Huang, Chun Sing Li, Renata Oballa, Yeeman K. Ramtohul, Kathryn Skorey, Paul Tawa, Hao Wang, Lei Zhang,